Karin Garre
Director/Board Member at EXPRES2ION BIOTECH HOLDING AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bent Frandsen | M | - | 8 years | |
| Christophe Thurieau | M | - |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 4 years |
| Per Stahl Skov | M | 78 |
University of Copenhagen
| 44 years |
| Jakob Knudsen | M | 56 | 7 years | |
| Keith Alexander | M | 48 | 4 years | |
| Martin Jensen | M | 64 | 14 years | |
| Sara Sande | F | 49 | 3 years | |
| Claude Bertrand | M | 62 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Farshad Guirakhoo | M | 70 | 1 years | |
| Benoit Chéron | M | - |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Max M. Søgaard | M | - | 11 years | |
| Pascal Lemaire | M | - |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jens Borum | M | 70 |
University of Copenhagen
| 5 years |
| Mads Krogsgaard Thomsen | M | 63 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.
University of Copenhagen
| 8 years |
| Steen Meier Rønborg | M | 70 |
University of Copenhagen
| 3 years |
| Mads Laustsen | M | 67 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 5 years |
| Thomas Dyrberg | M | 69 |
University of Copenhagen
| 7 years |
| Henrik Ramlau-Hansen | M | 67 |
University of Copenhagen
| 5 years |
| Peter Samuel Wulff | M | 71 |
University of Copenhagen
| 1 years |
| Martin Olin | M | 55 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 8 years |
| Jeffrey H. Buchalter | M | 67 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Bente Juel Riis | M | - |
University of Copenhagen
| 4 years |
| Lillan Rejkjaer | M | - |
University of Copenhagen
| 3 years |
| Birgit Kjældgaard Giwercman | M | - |
University of Copenhagen
| 3 years |
| Lars Eigen Møller | M | - |
University of Copenhagen
| 5 years |
| Sven Arne Blomberg | M | 74 |
University of Copenhagen
| 1 years |
| Lars-Erik Brenøe | M | 63 |
University of Copenhagen
| 3 years |
| Arne Gerlyng-Hansen | M | 68 |
University of Copenhagen
| 3 years |
| Janne Thyø Thomsen | F | 67 |
University of Copenhagen
| 3 years |
| Jørgen Nergaard Gøl | M | - |
University of Copenhagen
| 4 years |
| Karsten Witt | M | 68 |
University of Copenhagen
| 3 years |
| Peder Andersen | M | 72 |
University of Copenhagen
| 3 years |
| Peter Sam Loft | M | 67 |
University of Copenhagen
| 3 years |
| Melis Cosan Baban | M | - |
University of Copenhagen
| 3 years |
| Eske Rygaard-Hjalsted | M | - | 1 years | |
| Christoffer Søderberg | M | - |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Lisa Herold Ferbing | F | 65 |
University of Copenhagen
| 3 years |
| Gitte L. Pedersen | F | 61 | - | |
| Eivind Kolding | M | 64 |
University of Copenhagen
| 3 years |
| Lars Jannik Boberg-Ans | M | 68 |
University of Copenhagen
| 1 years |
| Mette Thorn | M | - | 2 years | |
| Susanne L. Biltoft | F | 61 |
University of Copenhagen
| 8 years |
| Karsten Kielland | M | - |
University of Copenhagen
| 4 years |
| Lisbeth Hald | F | - |
University of Copenhagen
| 4 years |
| Andreas Hasle | M | 69 |
University of Copenhagen
| 4 years |
| Jan Öhrström | M | 67 |
University of Copenhagen
| 3 years |
| Peter Helt Jacobsen Haahr | M | 56 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Jesper Mailind | M | 68 |
University of Copenhagen
| 1 years |
| Claus Tycho Bræstrup | M | 79 |
University of Copenhagen
| 3 years |
| Göran Albert Ando | M | 75 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Allan Rosetzsky | M | 76 | 12 years | |
| Niels Crone | M | - |
University of Copenhagen
| 1 years |
| Søren Lemonius | M | 59 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Henrik Lawaetz | M | 69 |
University of Copenhagen
| 3 years |
| Mikkel Rasmussen | M | 69 |
University of Copenhagen
| 3 years |
| Louis Illum Honoré | M | 62 |
University of Copenhagen
| 4 years |
| Carsten Krogsgaard Thomsen | M | 67 |
University of Copenhagen
| 1 years |
| Søren Gath Hansen | M | 70 |
University of Copenhagen
| 1 years |
| Kim Duus | M | 67 |
University of Copenhagen
| 1 years |
| Thomas Dywremose | M | - |
University of Copenhagen
| 4 years |
| Majken Schultz | M | 65 |
University of Copenhagen
| 1 years |
| Henrik Kjær | M | - |
University of Copenhagen
| 1 years |
| Brian R. Burr | M | - |
University of Copenhagen
| 4 years |
| Bernhard R. M. Ehmer | M | 69 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 2 years |
| Lars Rebien Sørensen | M | 69 |
University of Copenhagen
| 1 years |
| Mattis Ranthe | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 66 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Garre
- Personal Network
